Armaceutix Biotherapies

Armaceutix has developed a novel antibiotic for drug-resistant bacteria that acts as a Trojan horse to deliver antimicrobial silver ions to resistant organisms.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Honolulu, HI, US
  • Currency USD
  • Founded 2014
  • Employees 1
  • Website ponopharma.com

Company Summary

Drug-resistant bacteria are an increasing menace worldwide. Armaceutix Biotherapies seeks to complete the low-cost preclinical testing of its novel silver ion–based antibiotic, which has already demonstrated solid in vitro results against multiple drug-resistant bacteria. Rapid preclinical testing will confirm the value of this asset to larger pharma companies and allow a licensing deal within approximately two years of funding.

Team

  • Kevin Lye, MD, MBA
    CEO

    Former VP and Chief Medical Officer of Pono Pharma |||| Former Director of Clinical Research for Tissue Genesis, Inc.; 8+ years in startups |||| Gastric Pathobiology Research Group fellowship, Yale University |||| MD, Wake Forest School of Medicine |||| MBA with distinction, Hawai`i Pacific University |||| Undergraduate degrees summa cum laude, North Carolina State University [mathematics, biochemistry, biological sciences, and chemistry]

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free